Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept.
Takatori
Shino
S
Kamata
Yasuyuki
Y
Murosaki
Takamasa
T
Iwamoto
Masahiro
M
Minota
Seiji
S
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy; D003937:Diagnosis, Differential; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000097:blood* / Q000139:chemically induced* / Q000473:pathology
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D053495:Osteopontin; D000068800:Etanercept